The Texas House of Representatives voted today to approve House Bill 4014, advancing a proposal that would require a statewide study on the potential therapeutic use of psychedelics to treat PTSD, depression, and related conditions.
Texas State Capitol Building.
Filed by State Representative John Bucy (R), the bill directs the Health and Human Services Commission to conduct a comprehensive review of psychedelic therapies—including psilocybin, MDMA, and ketamine—as potential treatments for mental health disorders. The study would include a review of current clinical trials and scientific literature, as well as an evaluation of FDA actions related to these substances. The House passed the bill
HB 4014 calls for the commission to collaborate with Baylor College of Medicine and the Center for Psychedelic Research and Therapy at the University of Texas at Austin’s Dell Medical School. The goal is to assess treatment guidelines, best practices, and patient access—especially in anticipation of possible FDA approvals of psychedelic-assisted therapies in the coming years.
Under the measure, the commission would also be required to offer legislative recommendations to improve access to these therapies once federally approved. The final report would be due to lawmakers by December 1, 2026.
The bill is set to take effect on September 1, 2025, and would remain in place through September 2027.
